Holen Sie sich die Stockscreener-App
2.97
1.37%
0.04
Schlusskurs vom Vortag:
$2.93
Offen:
$2.91
24-Stunden-Volumen:
860.14K
Relative Volume:
2.81
Marktkapitalisierung:
$158.51M
Einnahmen:
$21.05M
Nettoeinkommen (Verlust:
$-89.22M
KGV:
-1.0277
EPS:
-2.89
Netto-Cashflow:
$-64.50M
1W Leistung:
+4.21%
1M Leistung:
-27.91%
6M Leistung:
-58.92%
1J Leistung:
-38.64%
1-Tages-Spanne:
$2.87
$3.05
1-Wochen-Bereich:
$2.81
$3.15
52-Wochen-Spanne:
$2.60
$9.69
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Firmenname
Tscan Therapeutics Inc
Sektor
Branche
Telefon
857-399-9500
Adresse
880 WINTER STREET, WALTHAM
Vergleichen Sie TCRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
2.97 | 158.51M | 21.05M | -89.22M | -64.50M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-16 | Eingeleitet | BTIG Research | Buy |
| 2024-05-13 | Eingeleitet | Needham | Buy |
| 2023-06-22 | Eingeleitet | Wedbush | Outperform |
Tscan Therapeutics Inc Aktie (TCRX) Neueste Nachrichten
2 "Strong Buy"-Rated Biotech Stocks With 303% To 446% Upside Potential - Barchart
tScan Therapeutics sees $385,768 purchase by Lynx1 Capital - Investing.com
Lynx1 Capital Management LP Increases Stake in TScan Therapeutics Inc - GuruFocus.com
TScan Therapeutics' SWOT analysis: TCR-T stock shows promise amid challenges - Investing.com India
TScan Therapeutics' SWOT analysis: TCR-T stock shows promise amid challenges By Investing.com - Investing.com South Africa
Wedbush Cuts Earnings Estimates for TScan Therapeutics - Defense World
Equities Analysts Offer Predictions for TCRX FY2026 Earnings - MarketBeat
TScan Therapeutics (NASDAQ:TCRX) Earns Buy Rating from Needham & Company LLC - Defense World
HC Wainwright Reaffirms Buy Rating for TScan Therapeutics (NASDAQ:TCRX) - Defense World
TScan Therapeutics (NASDAQ: TCRX) Issues Report on Updated Phase 1 Trial Data for ALLOHA Program**On December 9, 2024, TScan Therapeutics, Inc. released a comprehensive report on the latest developments surrounding its ALLOHA ™ Phase 1 trial - Defense World
The Analyst Landscape: 5 Takes On TScan Therapeutics - Benzinga
HC Wainwright Reiterates Buy Rating for TScan Therapeutics (NASDAQ:TCRX) - MarketBeat
TScan Therapeutics (NASDAQ:TCRX) Receives Buy Rating from Needham & Company LLC - MarketBeat
TScan Therapeutics Announces Promising Phase 1 Trial Results - TipRanks
TScan Therapeutics to Present Updated Data from the Ongoing - GlobeNewswire
Tscan Therapeutics to Present Updated Data from the Ongoing Alloha?? Phase 1 Heme Trial During Oral Session At the 66Th American Society of Hematology Annual Meeting and Exposition - Marketscreener.com
TScan's Blood Cancer Treatment Shows Breakthrough 92% Relapse Prevention in Phase 1 Trial Data - StockTitan
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years - GlobeNewswire
TScan Therapeutics Named Top Workplace in Massachusetts for Third Straight Year - StockTitan
TScan Therapeutics to Host Virtual KOL Event to Discuss - GlobeNewswire
TScan Therapeutics to Host KOL Event on Phase 1 Blood Cancer Trial Data at ASH - StockTitan
TScan issues stock in loan conversion - Investing.com
LMR Partners LLP Reduces Stock Position in TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat
Tscan therapeutics sees $4,113 stock purchase by Lynx1 capital - Investing.com India
TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock? - MSN
TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue Estimates - MSN
TScan Therapeutics (NASDAQ:TCRX) Earns “Buy” Rating from HC Wainwright - Defense World
FY2024 Earnings Estimate for TCRX Issued By Lifesci Capital - Defense World
FY2024 EPS Estimate for TScan Therapeutics Lifted by Analyst - Defense World
TScan Therapeutics (NASDAQ:TCRX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Wedbush Research Analysts Boost Earnings Estimates for TCRX - MarketBeat
TScan Therapeutics Inc (TCRX) Quarterly 10-Q Report - Quartzy
Wedbush Has Positive Forecast for TCRX FY2028 Earnings - MarketBeat
TScan Therapeutics' SWOT analysis: biotech stock poised for key catalysts By Investing.com - Investing.com Nigeria
TScan Therapeutics' SWOT analysis: biotech stock poised for key catalysts - Investing.com India
TScan Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Needham & Company LLC Reaffirms “Buy” Rating for TScan Therapeutics (NASDAQ:TCRX) - Defense World
TScan Therapeutics Reports Q3 2024 Financial Results - TipRanks
Tscan Therapeutics earnings beat by $0.06, revenue fell short of estimates - Investing.com Canada
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
TScan Reports Zero Relapses in Key Trial Despite 74% Revenue Drop; $271M Cash Runway - StockTitan
New Blood Cancer Treatment Shows Continued Response - Streetwise Reports
Tscan Therapeutics Inc’s (TCRX) 7.56% Increase Justifies A Second Look - Stocks Register
TScan Therapeutics' (TCRX) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Demystifying TScan Therapeutics: Insights From 4 Analyst Reviews - Benzinga
Does TScan Therapeutics (NASDAQ:TCRX) Have A Healthy Balance Sheet? - Simply Wall St
TScan Therapeutics' SWOT analysis: innovative therapy stock faces pivotal year - Investing.com Australia
TScan Therapeutics Announces Upcoming Oral Presentation of - GlobeNewswire
TScan's Blood Cancer Trial Shows Zero Relapses: Breakthrough Phase 1 Results | TCRX Stock News - StockTitan
Finanzdaten der Tscan Therapeutics Inc-Aktie (TCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tscan Therapeutics Inc-Aktie (TCRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner |
Dec 12 '24 |
Buy |
3.01 |
31,800 |
95,629 |
5,257,347 |
| Lynx1 Capital Management LP | 10% Owner |
Nov 15 '24 |
Buy |
4.34 |
947 |
4,114 |
5,225,547 |
| Klencke Barbara | Director |
Sep 23 '24 |
Buy |
5.29 |
5,000 |
26,450 |
45,000 |
| Klencke Barbara | Director |
Aug 23 '24 |
Buy |
5.69 |
5,000 |
28,450 |
35,000 |
| Klencke Barbara | Director |
Aug 26 '24 |
Buy |
5.53 |
5,000 |
27,650 |
40,000 |
| ZDRAVESKI ZORAN | See Remarks |
Aug 23 '24 |
Option Exercise |
3.38 |
157,186 |
531,520 |
169,402 |
| ZDRAVESKI ZORAN | See Remarks |
Aug 23 '24 |
Sale |
5.78 |
164,686 |
952,116 |
4,716 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):